Screener
Veracyte VCYT Testing revenue — Total Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Veracyte in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Veracyte’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 8:07 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001384101-26-000031
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Revenue: | ||
| Testing revenue | $135,091 | $107,309 |
| Product revenue | 3,679 | 3,580 |
| Biopharmaceutical and other revenue | 301 | 3,584 |
| Total revenue | 139,071 | 114,473 |
| Cost of revenue: | ||
| Cost of testing revenue | 33,306 | 28,260 |
| Cost of product revenue | 1,891 | 1,422 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Veracyte's testing revenue — total revenue?
- Veracyte (VCYT) reported testing revenue — total revenue of $135.09M in Q1 2026.
- How has Veracyte's testing revenue — total revenue changed year-over-year?
- Veracyte's testing revenue — total revenue increased by 25.9% year-over-year, from $107.31M to $135.09M.
- What is the long-term trend for Veracyte's testing revenue — total revenue?
- Over 4 years (2021 to 2025), Veracyte's testing revenue — total revenue has grown at a 27.2% compound annual growth rate (CAGR), from $188.18M to $493.15M.
- What does testing revenue — total revenue mean?
- This represents the total gross revenue generated from the company's diagnostic testing services and associated clinical products. It serves as a primary indicator of market adoption and the scale of the company's core diagnostic business operations.
Ask your AI about Veracyte's testing revenue — total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude